Harmful excipients in medicines for neonates in Spain
- 360 Downloads
Background Neonates may respond differently from adults to drug components. Hence, ingredients that seem safe in adults may not be safe in this age group. Objective To describe the content of harmful excipients in drugs used in our neonatal wards and compare the daily dose a neonate may receive with the accepted daily intake (ADI) in adults. Methods All drugs included in the hospital’s neonatal treatment guide were reviewed, using information from the package inserts or the summary of product characteristics. Those containing at least one harmful excipient (e.g., metabisulfite, sorbitol) were analyzed. Minimum and maximum usual daily drug doses were determined, and excipient exposure was estimated by extrapolation of the minimum and maximum of excipient referred to the active ingredient. These amounts were compared with ADIs for each excipient in adults. Results In total, 32 % of intravenous and 62 % of oral formulations used in neonates contained at least one harmful excipient. On quantitative analysis, 25 % of intravenous and 19 % of oral drugs contained harmful excipients exceeding the ADI in adults. Conclusion Several drugs commonly used to treat neonates contain harmful excipients in amounts that may exceed the ADI in adults. Clinicians should be aware of this to prescribe appropriate treatment in this population.
KeywordsExcipients Neonatal care Pediatrics Spain
Conflicts of interest
- 7.Commission of the European Communities. Report from the Commission on Dietary Food Additive Intake in the European Union [Internet] 2001; [cited 2015 Nov]. http://ec.europa.eu/transparency/regdoc/rep/1/2001/EN/1-2001-542-EN-F1-1.Pdf.
- 8.Rowe RC, Sheskey PJ, Quinn ME. Handbook of pharmaceutical excipients. 6th ed. London: Pharmaceutical Press; 2009.Google Scholar
- 9.European Medicines Agency, Committee for medicinal products for human use (CHMP). Reflection paper: formulations of choice for the paediatric population [Internet]. 2006 [cited 2015 Nov]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003782.pdf.